Xcellerant Ventures is a Scottsdale, Arizona–based venture capital firm specializing in early-stage investments within the healthtech, medtech, and biotech sectors. The firm is dedicated to funding technologies that enhance healthcare quality, efficiency, access, and delivery while reducing costs. Xcellerant emphasizes a "people first" philosophy, providing capital and strategic guidance to empower entrepreneurs in transforming healthcare.
Xcellerant Ventures targets early-stage companies in the healthtech, medtech, and biotech industries. The firm seeks dynamic founders who are humble, open to advice, and driven to effect positive change. Xcellerant prioritizes companies that have cleared regulatory hurdles, generate revenue, and demonstrate a clear path to rapid growth.
In April 2025, Xcellerant Ventures raised $7 million in partnership with AZ Venture Capital Inc. to invest in Arizona-based healthtech startups. This funding aims to bolster Arizona's position as a hub for healthcare innovation.
Leadership
The firm is led by Founding Partners John Shufeldt, MD; Douglas Sylvester, JD; and Christopher Yoo, Ph.D. The team also includes Principal Michael Shufeldt, MBA, and Associate & Controller TJ Kline.
Investment Strategy
Xcellerant focuses on early-stage investments in companies that address real-world healthcare problems through emerging technologies. The firm seeks startups with expedited paths to financial growth and emphasizes partnerships that improve healthcare quality, accessibility, efficiency, and affordability.
Notable Investments
Xcellerant's portfolio includes companies such as CRISPR QC, DeepLook Medical, Anuncia Medical, Lenoss Medical, and TruLite Health.
Notable Exits
The firm has achieved successful exits, including Rivia Health.
